Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (131-140 of 377) with videos related to

Pageof 38
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2016
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast CancerSibylle Loibl, Silvia Darb-Esfahani, Jens Huober, et al.
Geburtshilfe Und Frauenheilkunde|December 9, 2020
Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA AnalysisHans-Christian Kolberg, Thorsten Kühn, Maja Krajewska, et al.
Geburtshilfe Und Frauenheilkunde|December 18, 2020
Correction: Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA AnalysisHans-Christian Kolberg, Thorsten Kühn, Maja Krajewska, et al.
Breast Cancer Research and Treatment|January 8, 2014
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring studyAnn E McCullough, Patrizia Dell'orto, Monica M Reinholz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2020
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast CancerMin Huang, Joyce O'Shaughnessy, Jing Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2015
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)Claus Hanusch, Andreas Schneeweiss, Sibylle Loibl, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Bianca Lederer, Jens-Uwe Blohmer, et al.
Breast Cancer (Tokyo, Japan)|June 30, 2019
Fatal events during clinical trials: an evaluation of deaths during breast cancer studiesJenny Furlanetto, Gunter von Minckwitz, Bianca Lederer, et al.
Breast Cancer Research and Treatment|July 13, 2010
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trialIsabell Witzel, Sibylle Loibl, Gunter von Minckwitz, et al.
Cancer Research|February 3, 2006
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsGottfried E Konecny, Mark D Pegram, Natarajan Venkatesan, et al.
Pageof 38

Showing results (131-140 of 377) with videos related to

Sort By:
Pageof 38
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2016
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast CancerSibylle Loibl, Silvia Darb-Esfahani, Jens Huober, et al.
Geburtshilfe Und Frauenheilkunde|December 9, 2020
Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA AnalysisHans-Christian Kolberg, Thorsten Kühn, Maja Krajewska, et al.
Geburtshilfe Und Frauenheilkunde|December 18, 2020
Correction: Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA AnalysisHans-Christian Kolberg, Thorsten Kühn, Maja Krajewska, et al.
Breast Cancer Research and Treatment|January 8, 2014
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring studyAnn E McCullough, Patrizia Dell'orto, Monica M Reinholz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2020
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast CancerMin Huang, Joyce O'Shaughnessy, Jing Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2015
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)Claus Hanusch, Andreas Schneeweiss, Sibylle Loibl, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Bianca Lederer, Jens-Uwe Blohmer, et al.
Breast Cancer (Tokyo, Japan)|June 30, 2019
Fatal events during clinical trials: an evaluation of deaths during breast cancer studiesJenny Furlanetto, Gunter von Minckwitz, Bianca Lederer, et al.
Breast Cancer Research and Treatment|July 13, 2010
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trialIsabell Witzel, Sibylle Loibl, Gunter von Minckwitz, et al.
Cancer Research|February 3, 2006
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsGottfried E Konecny, Mark D Pegram, Natarajan Venkatesan, et al.
Pageof 38